CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Summary

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

Eligibility

Inclusion Criteria:

* 1\. Aged \>18 years old; ECOG 0 or 1;
* 2\. Patients with solid tumors;
* 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
* 4\. life expectancy \>=12 weeks.

Exclusion Criteria:

* 1\. Significant hepatic or renal dysfunction;
* 2\. Is pregnant or ready to pregnant;
* 3\. Cannot keep their states for half an hour;
* 4\. Refusal to join the clinical study;
* 5\. Suffering from claustrophobia or other mental diseases;
* 6\. Any other situation that researchers think it is not suitable to participate in the experiment.

Conditions2

Interventions1

Related trials

• 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients — Peking Union Medical College Hospital
• 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients — Peking Union Medical College Hospital
• A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma — Peking University First Hospital
• CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Hua Zhu
• Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73 — First Affiliated Hospital of Fujian Medical University
• Lung Nodule Detection Using Ultra-long FOV PET/CT — University Medical Center Groningen
• Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma — Peking University Cancer Hospital & Institute
• PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors — Hua Zhu

Browse More Trials